TNFR2 has been found to be overexpressed on highly suppressive tumor-infiltrating regulatory T cells (Treg), activated effector T cells (Teff), and many tumor cells in the tumor microenvironment, which makes TNFR2 a novel and very promising target for cancer immunotherapy. Based on the deep understanding of tumor immune microenvironment, SunHo has developed Teff agonist monoclonal antibody and Treg antagonist single-domain antibody against TNFR2, which will be applied for IND soon.